LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--May 8, 2006--BioSante Pharmaceuticals, Inc. (Amex:BPA - News) today announced that it will present positive results of several pre-clinical studies, demonstrating that its calcium phosphate (CaP) nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as an adjuvant for the development of an effective flu virus vaccine, including the potentially pandemic H5N1 bird flu. Dr. Steve Bell, vice president of research and pre-clinical development at BioSante, will present today at the 9th Annual Conference on Vaccine Research in Baltimore.
